ClinicalTrials.gg
RecruitingNCT03802695Updated Sep 29, 2026

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

A Phase 1 interventional study of OrcaGraft (Orca-Q) in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Mixed Phenotype Acute Leukemia, sponsored by Orca Biosystems, Inc.. Recruiting at 12 sites in United States. Open to participants aged 12 Years to 78 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Orca Biosystems, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2019; still recruiting 7 years 7 months later.
Updated Sep 29, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
12 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
95th of 1,907
300 · median 35
Started
2019
with 90 others
Phase 1
772 of 2,137
130 open now
Primary completion
2027-12
later than 276 of 464 live
Registered
1,527th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 95th largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 91 that started in 2019, is one of 772 in phase 1, reaches primary completion later than 276 of the 464 other live ones, and was the 1,527th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Mixed Phenotype Acute Leukemia
  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
12 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age at the time of enrollment:

    1. For MAC with fully matched donor (Arm A with 8/8 donor and Arm C) and NMA/RIC: Age ≥ 12 and ≤ 78 years
    2. For MAC with mismatched donors (Arm A with 7/8 donor and Arm B): Age ≥ 12 and ≤ 65 years
  2. Diagnosed acute myeloid, lymphoblastic or mixed phenotype leukemia, or high or very high risk myelodysplastic syndrome (MDS) either in complete remission (CR) or with ≤ 10 percent of blast cells in bone marrow (BM)
  3. Indicated for hematopoietic stem cell transplant (alloHCT)
  4. Matched to a 8/8 or 7/8 related or unrelated donor, or to a related haploidentical donor
  5. Estimated (eGFR) > 50 mL/minute (MAC with tacrolimus) or > 30 mL/minute (NMA/RIC or MAC without tacrolimus)
  6. Cardiac parameters: Cardiac ≥ 45 percent (MAC) or ≥ 40 percent (NMA/RIC)
  7. Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for ) ≥ 50 percent for MAC or ≥ 40 percent for NMA/RIC
  8. Liver function: Total \< 1.5 times (ULN) (MAC) or \< 3 times ULN (NMA/RIC); (ALT)/aspartate transaminase (AST) \< 3 times ULN (MAC) or \< 5 times ULN (NMA/RIC)
  9. Participants enrolling on NMA/RIC-alloHCT arms must be deemed unfit for a myeloablative alloHCT per assessment of the principal investigator (PI)

Key Exclusion Criteria:

  1. Prior alloHCT
  2. Currently receiving or other therapy except for approved disease-specific therapy for the patient's underlying hematologic . Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed
  3. Planned donor lymphocyte infusion (DLI)
  4. Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy) or alemtuzumab
  5. Positive anti-donor HLA antibodies against a mismatched allele in the selected donor
  6. Low performance score: For MAC: Performance Score (KPS) \< 70 percent, For NMA/RIC: \<60 percent
  7. High HCT-specific Comorbidity Index (HCT-CI): For MAC > 4, For NMA/RIC >6
  8. Uncontrolled bacterial, viral or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment
  9. Seropositive for (HIV)-1 or -2, human T-lymphotropic virus (HTLV)-1 or -2 or surface antigen (HbsAg) or anti- virus (HCV) antibody (Ab)
  10. Any uncontrolled disease requiring active immunosuppressive treatment
  11. Concurrent malignancies or active disease within 1 year, except non-melanoma skin cancers that have been curatively resected. Patients with concurrent indolent hematologic malignancies that do not require active treatment and are under active surveillance only (such as CLL, low-grade lymphomas, smoldering MM, MZL) may be included with the approval of Medical Monitor
  12. History of idiopathic or secondary myelofibrosis
  13. Women who are pregnant or breastfeeding
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Arm A

    Recipients with human leukocyte antigen (HLA)-identical related or unrelated or 1-allele mismatched (7/8 alleles) unrelated donor undergoing myeloablative conditioning (MAC); with single- or dual-agent graft-versus-host disease (GVHD) prophylaxis given

    Biological: OrcaGraft (Orca-Q)

  • Experimental
    Arm B

    Recipients with haploidentical-related donors undergoing MAC; with single- or dual-agent GVHD prophylaxis given

    Biological: OrcaGraft (Orca-Q)

  • Experimental
    Arm C

    Recipients with an HLA-identical related or unrelated donor undergoing MAC; no GVHD prophylaxis given

    Biological: OrcaGraft (Orca-Q)

  • Experimental
    Arm D

    Recipients with an HLA-identical related or unrelated donor undergoing non-myeloablative (NMA)/reduced intensity conditioning (RIC); with dual agent GVHD prophylaxis given

    Biological: OrcaGraft (Orca-Q)

  • Experimental
    Arm E

    Recipients with 1-allele mismatched (7/8 alleles) unrelated donor undergoing NMA/RIC; with dual-agent GVHD prophylaxis given

    Biological: OrcaGraft (Orca-Q)

  • Experimental
    Arm F

    Recipients with haploidentical-related donors undergoing NMA/RIC; with dual-agent GVHD prophylaxis given

    Biological: OrcaGraft (Orca-Q)

Interventions

  • BiologicalOrcaGraft (Orca-Q)

    engineered donor allograft

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities through Day +28 (dose escalation)

    Safety and tolerability of Orca-Q (formerly OrcaGraft) in adults undergoing myeloablative allogeneic hematopoietic cell transplantation (MA-alloHCT) will be evaluated by identification of the following dose limiting toxicities: Grade ≥ 3 infusion-related reaction or cytokine release syndrome, Grade ≥ 3 acute GVHD, Any Grade ≥ 3 treatment-related non-hematologic event not clearly related to the underlying malignancy, intercurrent infection, the HCT conditioning regimen, or other pre-existing medical condition

    Time frame: 28 Days after administration of Orca-Q/OrcaGraft

  2. Primary Graft failure through Day +28 (dose expansion)

    Primary graft failure in the dose expansion phase, defined as being alive without recovery of neutrophils during the evaluation period

    Time frame: 28 Days after administration of Orca-Q/OrcaGraft

Secondary outcomes

  1. Neutrophil Engraftment through Day +28

    Neutrophil engraftment defined as an absolute neutrophil count of \>/=500/mm3 for 3 consecutive days

    Time frame: 28 days after administration of Orca-Q/OrcaGraft

  2. Platelet Engraftment through Day +50

    Platelet engraftment is defined as achieving a platelet count \> 20,000/mm3 for 3 consecutive days without platelet transfusion in the preceding 7 days, by Day +50

    Time frame: 50 days after administration of Orca-Q/OrcaGraft

  3. Secondary Graft Failure through Day +100

    Secondary graft failure is defined as neutrophil engraftment followed by subsequent decline in absolute neutrophil counts \< 500 cells/μL, unresponsive to growth factor therapy, by Day +100

    Time frame: 100 days after administration of Orca-Q/OrcaGraft

  4. Acute GVHD through Day +100

    Acute GVHD will be staged and graded per Mount Sinai Acute GvHD International Consortium (MAGIC) Standardization criteria

    Time frame: 100 days after administration of Orca-Q/OrcaGraft

  5. Chronic GVHD through Day +365

    Chronic GVHD will be diagnosed per 2014 International NIH Chronic GVHD Diagnosis and Staging Consensus Working Group criteria

    Time frame: 365 days after administration of Orca-Q/OrcaGraft

  6. Incidence of Non-relapse Mortality (NRM) through Day +365

    NRM is defined as death without evidence of disease recurrence

    Time frame: 365 days after administration of Orca-Q/OrcaGraft

  7. Incidence of Disease Relapse through Day +365

    Recurrence of primary disease for transplant

    Time frame: 365 days after administration of Orca-Q/OrcaGraft

  8. GVHD-free and Relapse-free Survival (GRFS) through Day +365

    Survival free from GVHD and relapse

    Time frame: 365 days after administration of Orca-Q/OrcaGraft

  9. Disease-free Survival (DFS) through Day +365

    DFS is the time from date of transplant to death or relapse, whichever comes first.

    Time frame: 365 days after administration of Orca-Q/OrcaGraft

  10. Overall Survival through Day +365

    OS is defined as the time from the date of transplant to the date of death from any cause or, for surviving patients, to the date of last follow-up.

    Time frame: 365 days after administration of Orca-Q/OrcaGraft

07

Study locations

9 of 12 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Dec 2027, 104 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 104 months is above that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2019
First posted
Jan 14, 2019
StartActual
Apr 8, 2019
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Emory University is now Recruiting
Sep 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Emory University · Atlanta, United StatesContact added (no phone or email listed)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Emory University is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Emory University · Atlanta, United StatesContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03802695
Lead sponsor
Orca Biosystems, Inc.
Responsible party
Sponsor
First posted
Jan 14, 2019
Start date
Apr 8, 2019
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Tamara Zharkevich, MD, PhD
Contact
info@orcabiosystems.com
650-246-9601
James S McClellan, MD PhD
Contact
info@orcabiosystems.com
650-246-9601
James S McClellan, MD, PhD
study director · Orca Biosystems, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion